Drug Database
IM

immune globulin intravenous (Iveegam, Immuno / Iveegam EN)

✓ Approved

Baxter International, Inc. · Polyclonal Antibodies · Polyclonal Antibodies

What is immune globulin intravenous?

immune globulin intravenous is a polyclonal antibodies developed by Baxter International, Inc.. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesIveegam, Immuno, Iveegam EN
CompanyBaxter International, Inc.
Drug ClassPolyclonal Antibodies, Antibody
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Baxter International, Inc.

Therapeutic Indications

immune globulin intravenous is developed for 5 unique indications across 3 therapeutic areas.

Therapeutic AreaConditionPhase
Immune system disordersSelective IgG subclass deficiency✓ Approved
Infections and infestationsBorna virus infection✓ Approved
Musculoskeletal and connective tissue disordersDermatomyositisPreclinical
Musculoskeletal and connective tissue disordersPolymyositisPreclinical
Musculoskeletal and connective tissue disordersJuvenile idiopathic arthritisPreclinical

Related Research Articles

PubMedFoods (Basel, Switzerland)2026-10-16

Interpretable Small-Sample Hyperspectral Phenotyping of Wheat Protein Fractions via Order-Optimized Derivative Preprocessing and TabPFN.

Li Zihao Z, Chen Zhaoyang Z, Wu Yuxing Y, Fang Meng M et al.

Rapid phenotyping of water- and salt-soluble wheat protein fractions can support grain quality evaluation and breeding. Whole-wheat flour from water-nitrogen and water-fertilizer trials was used to predict measured albumin and globulin contents and their derived sum, termed the metabolic-protein sum (albumin + globulin). After systematically comparing various preprocessing, wavelength selection, and regression approaches, a framework combining order-optimized derivative preprocessing (ODP), a hybrid feature-selection approach based on minimum redundancy maximum relevance (MRMR) and recursive feature elimination (RFE) and a tabular prior-data fitted network (TabPFN) regressor provided consistently strong test-set performance. The optimal derivative orders were 1.0 for albumin and the metabolic-protein sum and 0.8 for globulin. The ODP-MRMR-RFE-TabPFN framework retained 147, 46, and 70 wavelengths for albumin, globulin, and the metabolic-protein sum, yielding test set coefficient of determination (R2) values of 0.847, 0.693, and 0.850; root mean square error (RMSE) values of 3.073, 0.951, and 3.368 mg g-1; and residual prediction deviation (RPD) values of 2.554, 1.804, and 2.586, respectively. Leave-one-cultivar-out validation revealed substantial variation in predictive performance across held-out cultivars, with R2 and RPD ranging from 0.282 to 0.736 and from 1.180 to 1.945, respectively, for albumin, and from 0.416 to 0.750 and from 1.308 to 2.001, respectively, for globulin. Thus, although albumin achieved quantitative-level performance under the random train-test split, this performance was not consistently maintained for unseen cultivars, whereas globulin was generally more suitable for screening. SHapley additive explanations (SHAP) and partial dependence plots (PDPs) revealed that visible wavelengths contributed strongly to all models, with near-infrared (NIR) wavelengths supplying complementary information for globulin and the metabolic-protein sum. Overall, this framework offers rapid, interpretable flour-based estimation of metabolically active wheat protein fractions.

PMID 42883614
Read full article →
PubMedNeurology and therapy2026-10-16

Real-World Health Care Resource Utilization, Adherence, and Persistence Following Subcutaneous IgPro20 Initiation Among US Patients with Chronic Inflammatory Demyelinating Polyneuropathy.

Kuatov Batyrkhan B, Weng Shicheng S, Hubsch Alphonse A, Undreiner Laurence L et al.

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, inflammatory peripheral nervous system disorder. Intravenous immunoglobulin (IVIG) has been the standard maintenance therapy, but since 2018, Immune Globulin Subcutaneous (Human), 20% liquid (IgPro20), a subcutaneous immunoglobulin (SCIG) therapy, has offered an alternative, demonstrating benefit in maintaining CIDP improvement and remission. This study aimed to evaluate real-world healthcare resource utilization (HCRU), adherence, and persistence following IgPro20 initiation in patients with CIDP, given limited real-world evidence on these SCIG-related outcomes. This observational, descriptive study used Optum's de-identified Clinformatics® Data Mart Database (Optum® CDM) data to examine adults with CIDP initiating IgPro20 (index date). Adult patients with ≥ 2 CIDP diagnosis claims at least 14 days apart and ≥ 6 months of enrollment pre- and post-index between January 1, 2014 and December 31, 2024 were included. Those on other SCIG products were excluded. Patients with CIDP initiating IgPro20 (N = 207) were 53.6% male, with a median age of 60.00 and few comorbidities. Acute care utilization was low at baseline and decreased further following IgPro20 initiation, with inpatient and emergency department visits per patient per year (PPPY) decreasing from 0.52 to 0.42 and from 1.00 to 0.85, respectively. Overall, outpatient (OP) visits increased from 60.62 PPPY pre-initiation to 92.61 PPPY in month 1 post-initiation, driven by visits for CIDP-related home administration, notably for nursing/home-care for self-administration training. OP visits subsequently declined to 67.43 PPPY by month 6 (n = 141). Most patients (69.1%) were highly adherent, and 63.8% remained persistent at 6 months. Patients on IgPro20 administration demonstrated therapy adherence and decreased utilization of resource-intensive settings. While initial increases in outpatient and home care visits likely reflect training for at-home therapy, other outpatient healthcare utilization decreased. High persistence and adherence indicate sustained, uninterrupted therapy.

PMID 42881325
Read full article →
PubMedFoods (Basel, Switzerland)2026-10-16

pH-Dependent Changes in the Structural and Functional Properties of Quinoa Protein Isolates in Aqueous Dispersions.

Astorga-Oquendo Liz L, Harte Federico M FM, Campanella Osvaldo H OH

Quinoa protein isolate (QPI) is an emerging plant-based ingredient with high nutritional quality and significant potential for sustainable and clean-label food formulations. However, limited understanding of the relationships among its major protein fractions, physicochemical characteristics, and functionality restricts its broader utilization in food systems. This study investigated the effects of pH conditions (3, 5, 7, 9, and 11) on the particle size distribution, soluble-solid recovery, interfacial properties (surface hydrophobicity, emulsification, and foaming), and albumin-globulin protein fraction profiles of three QPI aqueous dispersions (Q1, Q2, and Q3). Alkaline conditions significantly enhanced QPI soluble-solid recovery (from <20% to >70%) and interfacial functionality, which were associated with the dissociation of large protein aggregates (D50 > 3000 nm) into smaller, well-dispersed particles (D50 < 109 nm) and an increased abundance of soluble albumin-globulin protein fractions, particularly chenopodin. SDS-PAGE, densitometry, principal component analysis, and Pearson correlation supported strong relationships among soluble-solid recovery, particle size reduction, interfacial properties, and soluble albumin-globulin protein fractions. These findings provide an integrated understanding of pH-dependent structure-function relationships of quinoa proteins and demonstrate the potential of pH adjustment for modulating the functionality of QPI aqueous dispersions for sustainable, clean-label ingredients in emulsified foods, aerated systems, and next-generation protein-rich formulations.

PMID 42883608
Read full article →
PubMedBritish journal of cancer2026-10-16

Preclinical efficacy of a systemically-administered, second-generation STING agonist that promotes anti-tumour immunity in combination with radiotherapy.

Pedersen Malin M, Hubbard Lisa C LC, Foo Shane S, Patrikeev Anton A et al.

As potent triggers of innate immunity, STING agonists hold promise as active immunotherapeutic agents for cancer treatment. Second-generation STING agonists, suitable for systemic delivery, are being investigated in preclinical research and have entered clinical trials. Here, the novel synthetic STING agonist, BI-1703880 (STINGa), was investigated for anti-tumour and immunological effects. We used human and murine immune and tumour cells to examine the effects of STINGa in vitro, and preclinical cancer mouse models to investigate effects in vivo. We show that STINGa activates the STING pathway and results in a transient and dose-dependent upregulation and secretion of interferons and proinflammatory cytokines in vitro and in vivo. We show that intravenous administration of repeated dosing with low-dose STINGa is well tolerated. We report that radiotherapy (RT) and STING agonism synergises to generate innate immune cell and CD8+ T cell responses that control tumour growth. RT/STINGa upregulated PD-L1, PD-1 and CTLA-4 in the tumour microenvironment. Our findings show that combining RT/STINGa with immune checkpoint inhibitors further increases therapeutic benefit. Our data confirm STING as a therapeutic target in cancer and support the clinical development of BI1703880 STING agonist, thereby suggesting radiotherapy as a potential combination for enhancing anti-tumour efficacy.

PMID 42881240
Read full article →
PubMedAnnals of hematology2026-10-16

Donor-source-specific competing risks of relapse and non-relapse mortality in adult B-ALL allogeneic hematopoietic stem cell transplantation on a rabbit antithymocyte globulin-based platform.

Choi Dae-Ho DH, Jung Chul Won CW, Jang Jun Ho JH

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a cornerstone of therapy for adult B-cell acute lymphoblastic leukemia (B-ALL), yet simultaneous comparison of all four major donor categories within a single transplant platform is scarce. We retrospectively analyzed 190 consecutive adults with B-ALL undergoing first allo-HSCT (2008-2025) at a single center on a predominantly rabbit antithymocyte globulin (rATG)-based myeloablative platform: matched sibling (MSD, n = 72), matched unrelated (MUD, n = 46), mismatched unrelated (MMUD, n = 40), and haploidentical (Haplo, n = 32) donors. Cumulative incidence of relapse (CIR) and non-relapse mortality (NRM) were compared in a competing-risk framework (Fine-Gray regression). Five-year overall survival did not differ significantly across donor groups (range 31.6-59.2%; P = 0.14). Competing-risk analysis revealed opposing gradients: five-year CIR decreased from MSD (38.5%) to Haplo (23.8%; P = 0.40), whereas NRM increased from MSD (13.3%) to Haplo (43.5%; P = 0.01). Relapse-free survival did not differ (P = 0.43). Haploidentical transplantation was independently associated with higher NRM (subdistribution hazard ratio [sHR] 4.44; P < 0.001) but not relapse, compared with MSD. NRM was infection-related in 29/39 patients (74%; 83% in Haplo), whereas graft-versus-host disease (GVHD)-related deaths were rare. After inverse-probability-of-treatment weighting, NRM remained higher in haploidentical recipients (31.9% vs. 17.7%), while the apparent CIR advantage attenuated (38.2% vs. 34.8%). Within a predominantly rATG-based platform, donor source produced opposing gradients of relapse and NRM, with the apparent haploidentical relapse advantage largely explained by age and era confounding. The persistent NRM excess in haploidentical recipients was driven predominantly by infection rather than GVHD. These platform-specific findings support transitioning to post-transplant cyclophosphamide (PTCy)-based approaches.

PMID 42881285
Read full article →
PubMedJournal of pediatric ophthalmology and strabismus2026-10-16

Performance of Automated Vision Screening and Refraction in Young Children in Belize.

Istre-Wilz Hannah H, Barnwell Eliza E, Scircle Emily J EJ, Trivedi Rupal R et al.

To determine how automated instrument-based screening with the Spot Vision Screener (SVS) (Welch Allyn, Inc/Baxter) compares with standard visual acuity testing in Belizean schoolchildren, and to compare refractive results of the SVS and QuickSee hand-held autorefractor (PlenOptika). During a school-based vision screening program in Orange Walk, Belize, SVS performance was evaluated against visual acuity testing as the reference standard. Children failing visual acuity per American Association for Pediatric Ophthalmology and Strabismus (AAPOS)/National Center for Children's Vision and Eye Health guidelines (20/30 for age 5 years and older, 20/40 for age 4 years, and 20/50 for age 3 years) were considered referrals. SVS performance was assessed under three referral criteria sets: manufacturer thresholds, AAPOS 2021 guidelines, and stricter exploratory thresholds. Agreement between the SVS and QuickSee hand-held autorefractor was analyzed using intraclass correlation coefficients and mean bias. Of 1,009 children screened, 692 had both visual acuity and SVS measurements; 11.6% failed visual acuity screening. SVS sensitivity and specificity varied by criteria: manufacturer (45.0%, 95.3%), AAPOS (31.25%, 97.7%), and stricter thresholds (61.24%, 82.0%). Positive predictive value ranged from 30.82% to 64.10%. Stricter criteria increased sensitivity but reduced specificity. Device agreement analysis (589 children) showed moderate correlation for cylinder (intraclass correlation coefficient = 0.724) and sphere (intraclass correlation coefficient = 0.557), with the SVS tending to report higher refractive magnitudes. Automated screening using the SVS is a good option in school settings and can complement visual acuity testing, particularly where resources are limited. Referral thresholds should be tailored to program priorities to balance sensitivity and specificity. Agreement between the SVS and QuickSee supports their utility for efficient refractive assessment in community-based programs.

PMID 42885598
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about immune globulin intravenous